TIDMSNG
RNS Number : 5038I
Synairgen plc
12 August 2021
Press release
Synairgen plc
('Synairgen' or the 'Company')
Exercise of Options
and Total Voting Rights
Southampton, UK - 12 August 2021: Synairgen plc (LSE: SNG), the
respiratory company developing inhaled interferon beta (IFN-beta)
for the treatment of severe viral lung infections, announces today
that it has allotted 1,427,423 new ordinary shares of 1 pence each
in the capital of the company ("Ordinary Shares") following the
exercise of share options ("Option Exercise") by certain directors
of the Company as set out in the table below.
The options that have been exercised were due to expire in
September 2021. Certain of the new ordinary shares have been sold,
at a price of 140p, to meet the tax and subscription costs
associated with the exercise, with the remaining shares being
retained by the directors. Following the exercise and subsequent
sale, the holdings of the three directors are shown below:
Director New Ordinary New Ordinary Resultant Resultant % of Total
Shares Shares Options Ordinary Voting
Issued Sold Shares Rights
Richard
Marsden 538,063 296,959 2,279,513 995,771 0.49%
------------- ------------- ---------- ---------- -----------
Dr Phillip
Monk 400,212 220,878 1,646,323 423,934 0.21%
------------- ------------- ---------- ---------- -----------
John Ward 489,148 269,963 1,772,958 734,092 0.36%
------------- ------------- ---------- ---------- -----------
Application has been made to the London Stock Exchange for the
new Ordinary Shares to be admitted to trading on AIM and dealings
are expected to commence on or around the 19th August 2021.
The new Ordinary Shares rank pari passu with the existing
Ordinary Shares in the Company. Following the Option Exercise, the
Company's issued share capital will consist of 201,341,825 Ordinary
Shares. Accordingly, the figure of 201,341,825 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and
development company founded by University of Southampton Professors
Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product
candidate, SNG001 (inhaled interferon beta) for the treatment of
COVID-19. SNG001 is potentially the first host-targeted
broad-spectrum antiviral treatment delivered directly into the
lungs. The Company is evaluating nebulised SNG001 in its Phase III
clinical programme, which has been deemed an Urgent Public Health
study by the UK's National Institute for Health Research (NIHR).
SNG001 has also been granted Fast Track status from the US Food and
Drug Administration (FDA). In a Phase II trial, COVID-19 patients
with marked/severe breathlessness demonstrated a threefold greater
chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the company's obligations under Article 17 of MAR.
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Marsden
2. Reason for notification
a) Position / status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Exercise of options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Exercise of options
c) Price(s) and volume(s) Price(s) Volume(s)
1p 538,063
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Marsden
2. Reason for notification
a) Position / status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Sale of ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
140p 296,959
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Dr Phillip Monk
2. Reason for notification
a) Position / status Chief Scientific Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Exercise of options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Exercise of options
c) Price(s) and volume(s) Price(s) Volume(s)
1p 400,212
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Dr Phillip Monk
2. Reason for notification
a) Position / status Chief Scientific Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Sale of ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
140p 220,878
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name John Ward
2. Reason for notification
a) Position / status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Exercise of options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Exercise of options
c) Price(s) and volume(s) Price(s) Volume(s)
1p 489,148
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name John Ward
2. Reason for notification
a) Position / status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Sale of ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
140p 269,963
----------
d) Aggregated information As above
Aggregated volume Price
e) Date of the transaction 12 August 2021
f) Place of the transaction London AIM
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMZGMRKZMGMZM
(END) Dow Jones Newswires
August 12, 2021 11:12 ET (15:12 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024